Patient Access & Affordability
  • About
    • Mission
    • Who We Are
    • Advisory Board
    • Patient Advisors
    • Members
    • Funding
    • Contact
  • Resources
    • Blog
    • Watch & Listen
    • Surveys
  • Publications
    • Research Briefings
    • Current Issues
    • Fast Facts
    • Policy Platform
  • Working Groups
    • Benefit Design
    • Rare Disease Health Technology Assessment
      • Featured Work
    • Biosimilars & Complex Generics
  • ICERWATCH
    • What is ICER?
    • ICER Glossary
    • Analysis and Commentary
    • Public Comments
Select Page
Statement for the Record to the Senate Finance Committee Health Insurance Coverage in America: Current and Future Role of Federal Programs October 20, 2021

Statement for the Record to the Senate Finance Committee Health Insurance Coverage in America: Current and Future Role of Federal Programs October 20, 2021

Nov 3, 2021

During the October 20, 2021, Senate Finance Hearing, Health Insurance Coverage in America: Current and Future Role of Federal Programs, the areas where each party agrees to disagree are stark, but the places where change for patients is possible exists. It is our aim...
Comments on ICER’s May 14th Draft Evidence Report, “JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis”

Comments on ICER’s May 14th Draft Evidence Report, “JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis”

Jun 11, 2021

On May 14th, 2021, ICER released a Draft Evidence Report entitled, “JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis.” Patients Rising Now responded to the request for comments on the report. The comments noted that complex health...
Comments on ICER’s May 5 Draft Evidence Report, “Aducanumab for Alzheimer’s Disease: Effectiveness and Value”

Comments on ICER’s May 5 Draft Evidence Report, “Aducanumab for Alzheimer’s Disease: Effectiveness and Value”

May 27, 2021

On May 5, 2021, ICER released its Draft Evidence Report entitled, “Aducanumab for Alzheimer’s Disease.”  Patients Rising Now submitted comments on the draft report.  As stated in the comments, the goal for researchers and clinicians – and hope for patients – is to...
Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.

Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.

Mar 11, 2021

Comments on ICER’s February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”.  Some of the concerns raised in the letter point out that...

Comments on ICER’s January 22 nd Draft Evidence Report, “Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value

Feb 19, 2021

On January 22, 2021, ICER released its Draft Evidence Report entitled, “Belimumab and Voclosporin for Lupus Nephritis: Effectiveness and Value.” Patients Rising Now submitted comments on the draft report. Some of the concerns raised in the letter include the...
Patients Rising NOW Comments on Draft Evidence Report “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value”

Patients Rising NOW Comments on Draft Evidence Report “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value”

Aug 21, 2019

Patients Rising NOW offers the following comments on ICER’s May 22nd draft report, “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy.” Our comments about the draft report are organized below into sections concerning: Patient and Family...
« Older Entries

Categories

  • Access & Affordability
  • Blog
  • Comments
  • ICERWatch
  • News
  • Opinion
  • QALY
  • Research
  • Resources
  • Statements
  • Uncategorized
  • Video

IPAA

700 12th St. NW, Suite 700
Washington, DC 20005
202-750-1186 |  info@accessandaffordability.org

The Patient Access & Affordability Project is a program of Patients Rising, a national 501(c)3 nonprofit organization, and is governed by the Patients Rising Board of Directors.

  • Facebook
  • Twitter
  • RSS